Intellia Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $15,048 | $23,017 | $13,782 | $14,245 |
Gross Profit | 12,846 | 17,002 | -65,167 | 14,245 |
EBITDA | -98,330 | -95,409 | -96,388 | -107,522 |
EBIT | -100,532 | -95,786 | -101,324 | -109,996 |
Net Income | -96,231 | -95,786 | -101,324 | -101,255 |
Net Change In Cash | 15,048 | 23,017 | 13,782 | 14,245 |
Free Cash Flow | -117,425 | -69,411 | -76,928 | -99,861 |
Cash | 134,697 | 155,464 | 193,389 | 156,172 |
Basic Shares | 118,490 | 108,376 | 110,188 | 103,732 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $67,671 | $57,877 | $36,275 | $52,121 |
Gross Profit | 51,748 | 47,592 | 27,299 | 44,549 |
EBITDA | -396,771 | -523,978 | -506,315 | -450,592 |
EBIT | -412,694 | -534,263 | -515,291 | -458,164 |
Net Income | -412,694 | -519,021 | -481,192 | -474,186 |
Net Change In Cash | 67,671 | 57,877 | 36,275 | 52,121 |
Cost of Revenue | 409,977 | |||
Free Cash Flow | -354,658 | -354,658 | -408,071 | -391,677 |
Cash | 155,464 | 189,182 | 226,748 | 523,506 |
Basic Shares | 108,376 | 98,849 | 88,770 | 76,972 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.81 |
2025-12-31 | -$0.83 |
2025-09-30 | -$0.92 |
2025-06-30 | -$0.98 |